Table 1.

VE against 1-year persistence of different combinations of HPV types

HPV type	ATP analysisa						ITT analysisb
	Arm	Women in ATP cohort, N	Women with events, n	Rate per 100 women, n (95% CI)	Rate reduction/ 100 women, n (95% CI)	Efficacy, % (95% CI)	Women in ITT cohort, N	Women with events, n	Rate per 100 women, n (95%CI)	Rate reduction/ 100 women, n (95%CI)	VE, % (95% CI)
H PV16,18	Vaccine	2,635	8	0.3 (0.1–0.6)	3.0 (2.5–3.3)	90.9c (82.0–95.9)	3,727	153	4.1 (3.5–4.8)	3.9 (2. 9–5.0)	49.0d (38.1–58.1)
	Control	2,677	89	3.3 (27–4.1)			3,739	301	8.1 (7.2–9.0)
HPV31, 33, 45	Vaccine	2,642	37	1.4 (1.0–1.9)	1.1 (0.4–1.8)	44.5 (17.5–63.1)	3,727	150	4.0 (3.4–4.7)	0.7 (−0.2 to 1.7)	15.5 (−5.0 to 32.0)
	Control	2,695	68	2.5 (2.0–3.2)			3,739	178	4.8 (4.1–5.5)
Other	Vaccine	2,643	230	8.7 (7.7–9.8)	−1.0 (−2.6 to 0.5)	−13.4 (−36.9 to 6.0)	3,727	559	15.0 (13.9–16.2)	−0.2 (−2.0 to 1.5)	−1.4 (−14.1 to 9.8)
oncogenic types	Control	2,697	207	7.7 (6.7–8.7)			3,739	553	14.8 (13.7–16.0)
Any	Vaccine	2,643	267	10.1 (9.0–11.3)	1.4 (−0.3 to 3.2)	12.4 (−3.2 to 25.6)	3,727	764	20.5 (19.2–21.8)	2.6 (0.5–4.7)	11.3 (2.2–19.5)
oncogenic type	Control	2,697	311	11.5 (10.4–12.8)			3,739	864	23.1 (21.8–24.5)

^aThe ATP cohort includes women who received all 3 doses within protocol-defined windows, complied with the protocol during the vaccination period, did not have a biopsy or treatment (loop electrosurgical excision procedure [LEEP]) before the 6-month visit, and were HPV DNA negative (by PCR) for at least one of the HPV types in the end point at enrollment and at the 6-month visit.

^bITT cohorts include all women randomized and vaccinated, regardless of prevalence of infection and follow-up visits.

^cOne-sided P-value for test of VE equals 0 against the alternative that VE is greater than 0 is less than 10⁻¹⁷.

^dOne-sided P-value for test of VE equals 0 against the alternative that VE is greater than 0 is less than 10⁻¹¹.